Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | CYP3A5 | P20815 | 3/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2464999 | 0.84 | CACNA2D1 (0.40) | NR1H2KDM4E | |
| SCHEMBL17974973 | 0.81 | KCNA5 (0.44) | CYP3A4CYP3A5KCNA5CYP19A1KDM4E | |
| SCHEMBL20724247 | 0.80 | CYP3A4 (0.44) | CYP3A4CYP3A5KCNA5KCNH2NR1H2 | |
| SCHEMBL17963323 | 0.74 | CYP3A4 (0.46) | CYP3A4CYP3A5KCNA5CYP19A1 | |
| SCHEMBL10044245 | 0.69 | CYP19A1 (0.49) | CYP3A4CYP3A5KCNA5CYP19A1 | |
| SCHEMBL29756226 | 0.69 | CYP3A4 (0.49) | CYP3A4CYP3A5KCNA5KCNH2CYP19A1 | |
| SCHEMBL13887338 | 0.68 | KCNA5 (0.53) | CYP3A4CYP3A5KCNA5NR1H2CYP19A1 | |
| SCHEMBL27888098 | 0.68 | CYP19A1 (0.52) | CYP3A4CYP3A5KCNA5CYP19A1 | |
| SCHEMBL17974910 | 0.68 | MKNK1 (0.44) | CYP3A4KCNA5CYP19A1 | |
| SCHEMBL31252158 | 0.67 | KDM4E (0.47) | CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202378-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180009805-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| EP-3250571-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| WO-2016123391-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016123391-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202378-B2 | Therapeutic compounds and uses thereof | TAF1, TAF1L, TAF1B | CYP3A4 4039/4885CYP3A5 3354/4885KCNA5 4220/4885 |
| US-20180009805-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | TAF1, TAF1L, TAF1B | CYP3A4 4039/4885CYP3A5 3354/4885KCNA5 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.